Repatha Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of hyperlipidemia, limitations of statin-only therapies, growing diagnosis of familial hypercholesterolemia, expansion of cardiovascular specialty care, availability of biologic lipid therapies.

The growth in the forecast period can be attributed to increasing demand for advanced cardiovascular treatments, rising adoption of combination lipid management strategies, expansion of preventive cardiology practices, growing focus on personalized cholesterol management, increasing investment in biologic drug development. Major trends in the forecast period include increasing adoption of pcsk9 inhibitors, rising use of injectable lipid-lowering therapies, growing focus on cardiovascular risk reduction, expansion of biologic cholesterol treatments, enhanced emphasis on long-term lipid management.

The growing prevalence of cardiovascular diseases is expected to drive the growth of the repatha market going forward. Cardiovascular diseases (CVDs) include conditions affecting the heart and blood vessels, such as coronary artery disease, heart attacks, strokes, and hypertension. The rising prevalence of CVDs is linked to factors like poor diet, sedentary lifestyle, smoking, excessive alcohol consumption, high blood pressure, and genetic predisposition. Repatha (evolocumab) helps manage cardiovascular diseases by lowering LDL cholesterol levels, reducing the risk of heart attacks, strokes, and other cardiovascular events in patients with high cholesterol or atherosclerotic cardiovascular disease. For instance, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, about 7.6 million people in the UK are affected by heart and circulatory diseases, including 4 million men and 3.6 million women. This number could increase by 1 million by 2030 and by 2 million by 2040. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the repatha market.

The rising obesity rate is expected to accelerate the growth of the repatha market going forward. Obesity refers to the proportion of individuals in a population classified as obese based on body mass index (BMI). The increase in obesity is driven by poor dietary habits, high consumption of processed and calorie-dense foods, sedentary lifestyles, lack of physical activity, and genetic factors. Repatha is being investigated for potential benefits in obesity management by helping reduce cholesterol levels and improve metabolic health, although its primary use remains in controlling hyperlipidemia. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, the proportion of the population with obesity increased from 13% to 19% on average across OECD countries. Therefore, the rising obesity rate is driving the growth of the repatha market.

The increasing prevalence of high cholesterol is expected to support the growth of the repatha market going forward. High cholesterol refers to elevated levels of low-density lipoprotein (LDL) cholesterol in the blood, increasing the risk of cardiovascular diseases like heart attacks, strokes, and coronary artery disease. High cholesterol is influenced by factors such as poor diet, lack of physical activity, genetics, obesity, smoking, and excessive alcohol consumption. Repatha (evolocumab) lowers high cholesterol by inhibiting the PCSK9 protein, enhancing the liver’s ability to remove LDL (bad) cholesterol from the bloodstream, thereby significantly reducing LDL levels. For instance, in August 2025, according to BioMed Central (BMC), a UK-based open-access academic publisher, the global prevalence was 28.8% for hypertriglyceridemia, 24.1% for hypercholesterolemia, 38.4% for low HDL-C, and 18.93% for high LDL-C. Men had a higher prevalence of hypertriglyceridemia (33.8% vs. 24.5% in women), while women showed a higher frequency of low HDL-C (40.5% vs. 34.1% in men). Therefore, the rising prevalence of high cholesterol is driving the growth of the repatha market.

Major companies operating in the repatha market are Amgen Inc.

North America was the largest region in the repatha market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the repatha market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the repatha market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the repatha market by increasing costs related to imported monoclonal antibody production materials, delivery devices, formulation components, and cold-chain logistics. Pharmaceutical markets in North America and Europe are most affected due to cross-border biologics manufacturing dependencies, while Asia-Pacific faces higher import pricing for branded therapies. These tariffs are influencing drug pricing, reimbursement negotiations, and patient access. At the same time, they are encouraging regional biologics manufacturing expansion, localized packaging operations, and long-term supply chain diversification strategies.

The repatha market research report is one of a series of new reports that provides repatha market statistics, including repatha industry global market size, regional shares, competitors with a repatha market share, detailed repatha market segments, market trends and opportunities, and any further data you may need to thrive in the repatha industry. This repatha market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Repatha (evolocumab) is a monoclonal antibody used to reduce cholesterol levels in patients with hyperlipidemia. It works by inhibiting PCSK9, a protein that limits the liver’s ability to remove LDL cholesterol from the bloodstream. Repatha is commonly prescribed for individuals who cannot reach target cholesterol levels through diet or statin therapy alone.

The primary indications for Repatha include primary hypercholesterolemia, homozygous familial hypercholesterolemia (FH), and atherosclerotic cardiovascular disease (CVD). Primary hypercholesterolemia is a condition characterized by elevated blood cholesterol, caused by genetic or lifestyle factors, which increases the risk of cardiovascular disease. Repatha is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by pediatric, adult, and geriatric patients.

The repatha market consists of sales of repatha injections and repatha pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.